Xos director logs 7,500-share sale, RSU grants
Xos, Inc. (XOS) reports an amended Form 4 for director Alice Yake, correcting prior transaction codes to reflect that certain dispositions were open‑market sales under a Rule 10b5-1 trading plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Xos, Inc. (XOS) reports an amended Form 4 for director Alice Yake, correcting prior transaction codes to reflect that certain dispositions were open‑market sales under a Rule 10b5-1 trading plan. On July 10, 2026 she received 60,584 RSUs subject to future vesting and 2,292 immediately vested RSUs in lieu of cash fees. She then sold 2,500 common shares on each of July 10, 13, and 14, 2026 at weighted average prices of $2.4916, $2.3483, and $2.3948 per share, respectively. The amendment states no other information from the original Form 4 has changed.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F4, F7, F2 | 2,500 | $2.3948 | $6K |
| Sale | Common Stock F4, F6, F2 | 2,500 | $2.3483 | $6K |
| Grant/Award | Common Stock F1, F2 | 60,584 | $0.00 | $0.00 |
| Grant/Award | Common Stock F3, F2 | 2,292 | $0.00 | $0.00 |
| Sale | Common Stock F4, F5, F2 | 2,500 | $2.4916 | $6K |
Footnotes (7)
- F1. The shares reported in this transaction represent Restricted Stock Units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock upon settlement. The RSUs vest on the earlier of (i) the first anniversary of the Grant date and (ii) the day before the Company's 2027 Annual Meeting, subject to the Reporting Person's continuous service with Xos, Inc. through the vesting date.
- F2. Includes 60,584 unvested RSUs.
- F3. The shares reported in this transaction represent RSUs that were issued to the Reporting Person in lieu of the cash retainer fees for the Reporting Person's service as a non-employee director and as Nominating and Corporate Governance Committee Chair in the second quarter of 2026. The RSUs reported vested immediately on the date of grant.
- F4. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- F5. Represents weighted average sales price. The shares were sold at prices ranging from $2.46 to $2.59. The Reporting Person will provide upon request, to the SEC, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F6. Represents weighted average sales price. The shares were sold at prices ranging from $2.325 to $2.44. The Reporting Person will provide upon request, to the SEC, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F7. Represents weighted average sales price. The shares were sold at prices ranging from $2.35 to $2.43. The Reporting Person will provide upon request, to the SEC, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
Restricted Stock Units ("RSUs") financial
weighted average sales price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the amended Form 4/A disclose for XOS director Alice Yake?
What correction does this Form 4/A make for XOS?
What are the key terms of the 60,584 RSUs reported for XOS?
What RSUs did Alice Yake receive instead of cash fees from XOS?
AI-generated analysis. How Rhea-AI works. Not financial advice.